Firm Advises KYTHERA Biopharmaceuticals in US$2.1 Billion Acquisition by Allergan

Latham’s leading Life Sciences team guides long-time client KYTHERA in major transaction for its aesthetics portfolio.

June 17, 2015

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, have announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion, subject to the fulfillment of certain customary conditions. 

Latham & Watkins LLP represents KYTHERA in the transaction with a corporate deal team led from the firm’s Silicon Valley office by partners Alan Mendelson, Mark Roeder and Josh Dubofsky, with associates John Harrison, Deeptha Mathavan, Benjamin Liss, Owais Mahesri and Albert Yeh. Advice is also being provided on public company representation by Silicon Valley partner Brian Cuneo, with associates Saied Pinto and Alexander White; on antitrust matters by San Francisco partner Karen Silverman and Washington, D.C. counsel Sydney Smith; on benefits and compensation matters by Silicon Valley partner James Metz and associate Ashley Wagner; on regulatory matters by Washington, D.C. partners John Manthei and Jennifer Archie, with San Francisco counsel Betty Pang and Washington, D.C. associates Elizabeth Richards, Susan Ebersole and Michael Dreyfuss; on intellectual property matters by Silicon Valley partner Judith Hasko and counsel Geoffrey Kuziemko; and on tax matters by San Francisco partner Kirt Switzer and Washington, D.C. partner Nicholas DeNovio, with Washington, D.C. associate Sean FitzGerald and Silicon Valley associate Jessica Chen.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.